EA202192090A1 - Антигенсвязывающие белки против гамма-цепи рецептора il2 - Google Patents
Антигенсвязывающие белки против гамма-цепи рецептора il2Info
- Publication number
- EA202192090A1 EA202192090A1 EA202192090A EA202192090A EA202192090A1 EA 202192090 A1 EA202192090 A1 EA 202192090A1 EA 202192090 A EA202192090 A EA 202192090A EA 202192090 A EA202192090 A EA 202192090A EA 202192090 A1 EA202192090 A1 EA 202192090A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- gamma chain
- antigen binding
- binding proteins
- antibodies
- receptor gamma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962799851P | 2019-02-01 | 2019-02-01 | |
| PCT/US2020/015841 WO2020160242A1 (en) | 2019-02-01 | 2020-01-30 | Anti-il2 receptor gamma antigen-binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202192090A1 true EA202192090A1 (ru) | 2021-10-20 |
Family
ID=69740681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202192090A EA202192090A1 (ru) | 2019-02-01 | 2020-01-30 | Антигенсвязывающие белки против гамма-цепи рецептора il2 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11629195B2 (enExample) |
| EP (2) | EP4717318A2 (enExample) |
| JP (3) | JP7544724B2 (enExample) |
| KR (1) | KR20210123350A (enExample) |
| CN (3) | CN120157765A (enExample) |
| AU (2) | AU2020214812B2 (enExample) |
| BR (1) | BR112021014074A2 (enExample) |
| CA (1) | CA3126117A1 (enExample) |
| CL (1) | CL2021002008A1 (enExample) |
| CO (1) | CO2021009693A2 (enExample) |
| DK (1) | DK3917962T3 (enExample) |
| EA (1) | EA202192090A1 (enExample) |
| FI (1) | FI3917962T3 (enExample) |
| IL (1) | IL284579A (enExample) |
| MX (1) | MX2021008958A (enExample) |
| MY (1) | MY203138A (enExample) |
| PH (1) | PH12021500031A1 (enExample) |
| PT (1) | PT3917962T (enExample) |
| SG (1) | SG11202107272SA (enExample) |
| WO (1) | WO2020160242A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020160242A1 (en) * | 2019-02-01 | 2020-08-06 | Regeneron Pharmaceuticals, Inc. | Anti-il2 receptor gamma antigen-binding proteins |
| EP4139341A1 (en) * | 2020-04-21 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| JP2024541048A (ja) * | 2021-11-02 | 2024-11-06 | シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド | 抗ｃｄ１２２抗体、抗ｃｄ１３２抗体、及び関連する二重特異性結合性タンパク質 |
| CN114990206B (zh) * | 2022-06-02 | 2023-04-07 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | Common γ-chain受体作为药物靶点在制备治疗狼疮性肾炎药物中的应用 |
| JP2025523802A (ja) | 2022-07-13 | 2025-07-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 分析物を検出するための弱酸性免疫アッセイ |
| KR20250075694A (ko) | 2022-09-28 | 2025-05-28 | 리제너론 파마슈티칼스 인코포레이티드 | 세포 기반 요법을 강화하기 위한 항체 저항성 변형 수용체 |
| CN116162154B (zh) * | 2022-10-21 | 2024-06-11 | 珠海泰诺麦博制药股份有限公司 | 抗人巨细胞病毒抗体及其用途 |
| WO2024138175A1 (en) * | 2022-12-22 | 2024-06-27 | Forte Subsidiary, Inc. | Methods of treating acute and chronic graft versus host diseases |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026033139A1 (en) | 2024-08-09 | 2026-02-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US5693489A (en) | 1984-03-30 | 1997-12-02 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| JP3255699B2 (ja) | 1992-04-23 | 2002-02-12 | 味の素株式会社 | ヒトＩＬ−２レセプターγ鎖分子 |
| US6576236B1 (en) | 1994-07-01 | 2003-06-10 | Dana Farber Cancer Institute | Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain |
| WO1997017360A2 (en) | 1995-11-09 | 1997-05-15 | Dana-Farber Cancer Institute | Methods for modulating t cell responses by manipulating a common cytokine receptor gamma chain |
| AU2937597A (en) * | 1996-05-10 | 1997-12-05 | Biogen, Inc. | Common gamma chain blocking agents |
| US6861227B2 (en) | 1998-03-19 | 2005-03-01 | Human Genome Sciences, Inc. | Antibodies to cytokine receptor common gamma chain like |
| AU2001247899A1 (en) | 2000-04-06 | 2001-10-23 | Genetics Institute, Llc | Polynucleotides encoding novel secreted proteins |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| EP2560994B1 (en) | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
| EP2663334A4 (en) * | 2011-01-10 | 2016-01-13 | Univ Emory | ANTIBODIES AGAINST INFLUENZA |
| PL3366705T3 (pl) | 2012-09-12 | 2023-09-18 | Genzyme Corporation | FC zawierające polipeptydy o zmienionej glikozylacji i zmniejszonej funkcji efektorowej |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| PT3172227T (pt) | 2014-07-21 | 2019-12-06 | Delinia Inc | Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis |
| PT3328894T (pt) | 2015-08-06 | 2019-02-13 | Agency Science Tech & Res | Anticorpos de cadeia comum gama/il2rbeta |
| CN115636880A (zh) * | 2015-10-23 | 2023-01-24 | 辉瑞有限公司 | 抗il-2抗体及其组合物和用途 |
| WO2018156649A1 (en) | 2017-02-22 | 2018-08-30 | Flagship Pioneering, Inc. | Compositions of t cell modulator (tcm) molecules and uses thereof |
| WO2020160242A1 (en) * | 2019-02-01 | 2020-08-06 | Regeneron Pharmaceuticals, Inc. | Anti-il2 receptor gamma antigen-binding proteins |
-
2020
- 2020-01-30 WO PCT/US2020/015841 patent/WO2020160242A1/en not_active Ceased
- 2020-01-30 FI FIEP20708887.3T patent/FI3917962T3/fi active
- 2020-01-30 MX MX2021008958A patent/MX2021008958A/es unknown
- 2020-01-30 JP JP2021544532A patent/JP7544724B2/ja active Active
- 2020-01-30 US US16/776,928 patent/US11629195B2/en active Active
- 2020-01-30 CN CN202510314674.7A patent/CN120157765A/zh active Pending
- 2020-01-30 EP EP26156344.9A patent/EP4717318A2/en active Pending
- 2020-01-30 SG SG11202107272SA patent/SG11202107272SA/en unknown
- 2020-01-30 CN CN202080012091.4A patent/CN113474370B/zh active Active
- 2020-01-30 PH PH1/2021/500031A patent/PH12021500031A1/en unknown
- 2020-01-30 DK DK20708887.3T patent/DK3917962T3/da active
- 2020-01-30 MY MYPI2021003809A patent/MY203138A/en unknown
- 2020-01-30 PT PT207088873T patent/PT3917962T/pt unknown
- 2020-01-30 EP EP20708887.3A patent/EP3917962B1/en active Active
- 2020-01-30 EA EA202192090A patent/EA202192090A1/ru unknown
- 2020-01-30 BR BR112021014074A patent/BR112021014074A2/pt unknown
- 2020-01-30 CA CA3126117A patent/CA3126117A1/en active Pending
- 2020-01-30 CN CN202510314681.7A patent/CN120157766A/zh active Pending
- 2020-01-30 AU AU2020214812A patent/AU2020214812B2/en active Active
- 2020-01-30 KR KR1020217027926A patent/KR20210123350A/ko not_active Ceased
-
2021
- 2021-07-04 IL IL284579A patent/IL284579A/en unknown
- 2021-07-23 CO CONC2021/0009693A patent/CO2021009693A2/es unknown
- 2021-07-29 CL CL2021002008A patent/CL2021002008A1/es unknown
-
2023
- 2023-02-15 US US18/169,345 patent/US20230279131A1/en active Pending
-
2024
- 2024-08-21 JP JP2024139375A patent/JP7760010B2/ja active Active
-
2025
- 2025-10-10 JP JP2025171516A patent/JP2026016453A/ja active Pending
- 2025-10-16 AU AU2025252566A patent/AU2025252566A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022519068A (ja) | 2022-03-18 |
| DK3917962T3 (da) | 2026-04-13 |
| AU2020214812A1 (en) | 2021-09-23 |
| AU2025252566A1 (en) | 2025-11-06 |
| MY203138A (en) | 2024-06-11 |
| BR112021014074A2 (pt) | 2021-11-23 |
| EP4717318A2 (en) | 2026-04-01 |
| US11629195B2 (en) | 2023-04-18 |
| CO2021009693A2 (es) | 2021-08-09 |
| CN120157766A (zh) | 2025-06-17 |
| JP2026016453A (ja) | 2026-02-03 |
| KR20210123350A (ko) | 2021-10-13 |
| PH12021500031A1 (en) | 2022-05-02 |
| CA3126117A1 (en) | 2020-08-06 |
| JP7544724B2 (ja) | 2024-09-03 |
| JP2024161548A (ja) | 2024-11-19 |
| CN113474370B (zh) | 2025-04-01 |
| AU2020214812B2 (en) | 2025-10-02 |
| IL284579A (en) | 2021-08-31 |
| FI3917962T3 (fi) | 2026-04-24 |
| CN120157765A (zh) | 2025-06-17 |
| CL2021002008A1 (es) | 2022-02-04 |
| EP3917962B1 (en) | 2026-03-18 |
| CN113474370A (zh) | 2021-10-01 |
| EP3917962A1 (en) | 2021-12-08 |
| PT3917962T (pt) | 2026-03-30 |
| US20200247894A1 (en) | 2020-08-06 |
| JP7760010B2 (ja) | 2025-10-24 |
| WO2020160242A1 (en) | 2020-08-06 |
| US20230279131A1 (en) | 2023-09-07 |
| MX2021008958A (es) | 2021-11-04 |
| SG11202107272SA (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202192090A1 (ru) | Антигенсвязывающие белки против гамма-цепи рецептора il2 | |
| ZA202308021B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| CR20200579A (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| EA202090718A1 (ru) | Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1) | |
| MX2023010499A (es) | Anticuerpos heterodimericos que se unen a cd3 y cldn6. | |
| DE602006013029D1 (de) | Anti-egfr-antikörper | |
| WO2020172621A8 (en) | Cd33 antibodies and methods of using the same to treat cancer | |
| MX2021007093A (es) | Anticuerpos btla. | |
| EA202091747A1 (ru) | Составы антитела b7-h4 | |
| PH12022551398A1 (en) | Anti-mertk antibodies and methods of use thereof | |
| ZA202302392B (en) | Antibodies against ilt2 and use thereof | |
| MX2023002106A (es) | Anticuerpos fgfr3 y metodos de uso. | |
| BR112021018632A2 (pt) | Moléculas de ligação ao cd3 | |
| EA202191656A1 (ru) | Анти-il-36 антитела и способы их применения | |
| PH12021553197A1 (en) | Anti-cd47 antibodies and uses thereof | |
| MX2025001452A (es) | Anticuerpos anti-ccr8 y metodos de uso | |
| MX2025004652A (es) | Conjugados de farmaco-anticuerpo del cumulo de diferenciacion (cd70) y metodos de uso de los mismos | |
| MX2022006148A (es) | Metodos para tratamiento del cancer usando anticuerpos anti-ox40 en combinacion con anticuerpos anti-tigit. | |
| MX2023012739A (es) | Anticuerpos anti-gitr y usos de estos. | |
| MX2025006929A (es) | Anticuerpos contra la proteína 1 que contiene dominio de cub (cdcp1) y usos de estos | |
| MX2023012300A (es) | Anticuerpos humanos contra artemina y metodos de uso de estos. | |
| MX2023013392A (es) | Anticuerpos para tratar alfa-sinucleinopatias. | |
| WO2022082030A3 (en) | Antigen-binding proteins and related methods of use | |
| MX2022003191A (es) | Terapias de combinacion con anticuerpos entpd2 y cd73. | |
| MX2021008453A (es) | Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos. |